The Brown University Child and Adolescent Psychopharmacology Update This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Marijuana exposures in young children rise in Colorado
Data from a children's hospital and a regional poison center in Colorado suggest that the state's recreational marijuana law has contributed to an increase in unintentional pediatric exposures with potential health effects. Most of the young patients that have been seen in these cases have had generally resolvable symptoms such as drowsiness and problems with balance, although in a handful of cases significant respiratory depression has occurred, a co‐author told CPU. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - September 25, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

As marijuana access expands, research seeks to shed light on use disorders
Given the high number of states that have either adopted or seriously considered measures allowing marijuana use for medical or recreational purposes, it remains surprising that many knowledge gaps persist regarding the health implications of wider access to the drug. Moreover, there is an even more gaping hole in the understanding of the trajectory of actual marijuana use disorders, compared with the field's familiarity with general trends in marijuana use. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - September 25, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

DEA keeps marijuana illegal but encourages more research into medical use
The Drug Enforcement Administration (DEA) this month stated that it would not reschedule marijuana, but rather would keep it on Schedule I of the Controlled Substances Act (CSA), the category reserved for drugs that have a high abuse potential and no accepted medical use in the United States. Petitioners had hoped that the DEA would place smoked marijuana on Schedule II, the category for drugs with high abuse potential but accepted medical use. Other drugs on Schedule I include heroin and methamphetamine; other drugs on Schedule II include cocaine and methadone, as well as dronabinol, which is synthetic THC, one of the act...
Source: The Brown University Child and Adolescent Psychopharmacology Update - September 25, 2016 Category: Psychiatry Tags: Medical Marijuana Source Type: research

Half of college students who misuse prescription stimulants have SUDs
Nonmedical use of stimulants is misuse, and in the college setting, where students may be misusing these medications in order to stay up late and study, it turns out that most, compared to controls, actually have psychiatric disorders, including attention‐ deficit hyperactivity disorder (ADHD), according to recent research. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - August 29, 2016 Category: Psychiatry Tags: Substance Use Source Type: research

FDA clears FAAH inhibitors for trials, says it will help with labeling for OTC naloxone
FDA finds drugs under investigation in the U.S. related to French BIA 10‐2474 drug do not pose similar safety risks (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - August 28, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

Research Roundup
New clinical guidelines proposed for fetal alcohol spectrum disorders Diabetes increases risk of mental health hospitalization for young people (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - August 28, 2016 Category: Psychiatry Tags: Research Roundup Source Type: research

Marijuana exposures in young children rise in Colorado, prompt vigilance
Data from a children's hospital and a regional poison center in Colorado suggest that the state's recreational marijuana law has contributed to an increase in unintentional pediatric exposures with potential health effects. A pediatric emergency medicine specialist who co‐authored the study told CPU that most of the young patients that have been seen in these cases have had generally resolvable symptoms such as drowsiness and problems with balance, although in a handful of cases significant respiratory depression has occurred. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - August 28, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

Nonpublication of pediatric RCTs twice as high for industry as academic ‐sponsored trials
Pediatric randomized clinical trials (RCTs) have specific challenges that can lead to discontinuation and nonpublication. Researchers looked at the prevalence of these and found that industry‐sponsored trials are less likely to be discontinued, probably due to the greater access to financial resources compared to academic trials. They also found that industry‐sponsored trials are more than twice as likely to go unpublished compared to academic trials, contributing to publication bias. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - August 28, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

AAP urges pediatricians to prescribe buprenorphine
In “Medication‐Assisted Treatment of Adolescents With Opioid Use Disorders,” published online August 22, the American Academy of Pediatrics (AAP) urges its members to make buprenorphine available to patients with opioid use disorders. A leading cause of morbidity and mortality among youth in the United States, opioid use disorders have effective treatments, both medications (methadone, buprenorphine, and naltrexone) and counseling, but access to appropriate treatment is restricted, especially for adolescents. The AAP noted that resources are needed to communicate information about the effective treatments, as well as...
Source: The Brown University Child and Adolescent Psychopharmacology Update - August 28, 2016 Category: Psychiatry Tags: Opioid Use Disorders Source Type: research

Sedating and activating side effects of first ‐time SGA use persist
The side effects of sedation and activation caused by first‐time use of antipsychotics in young people are possibly more linked to parameters such as age rather than the specific medication, according to new research. For the study, the researchers used the Second‐Generation Antipsychotic Treatment Indication, Effectiveness and Tolerability in Youth (SATIETY) study to assess activating and tranquilizing effects of second‐generation antipsychotics (SGAs) in youth. Four SGAs were studied: quetiapine, olanzapine, risperidone, and aripiprazole. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - July 27, 2016 Category: Psychiatry Tags: Schizophrenia Source Type: research

Remote breath ‐testing device approved for premarket clearance
Last month, the Food and Drug Administration granted 510(k) premarket clearance for the Soberlink Breathalyzer, a real‐time mobile‐breath sobriety technology. The device is for medical use by health care providers to remotely measure alcohol in human breath, for the purpose of aiding in the detection and monitoring of alcohol consumption in those who suffer from alcohol use disorders. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - July 25, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

How parental/caregiver substance use affects children
Pediatricians well know that it's not their patients who need treatment for substance use disorders (SUDs) — it's their patients' parents or caregivers. A clinical report published online last week by the American Academy of Pediatrics (AAP) gives recommendations on how pediatricians can screen families, what they are mandated to report, and how they can help the entire family in these situations. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - July 25, 2016 Category: Psychiatry Tags: News Source Type: research

AATOD white paper details how OTPs and buprenorphine providers can collaborate
A new report from the American Association for the Treatment of Opioid Dependence (AATOD) focuses on how opioid treatment programs (OTPs) can collaborate with other health care providers, including office‐based buprenorphine prescribers, on closing the treatment gap for opioid use disorders. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - July 25, 2016 Category: Psychiatry Tags: News Source Type: research

D ‐cycloserine found ineffective in CBT augmentation for pediatric OCD
Even after intervention with cognitive behavior therapy (CBT) for obsessive‐compulsive disorder (OCD), some patients still have symptoms. An antibiotic, D‐cycloserine, has been shown to enhance CBT outcomes for adults with OCD, but according to a new study, it is ineffective in youth. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - July 25, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

Childhood and adulthood ADHD two separate syndromes: Population study
It is possible for young adults to develop attention‐deficit hyperactivity disorder (ADHD) without having had childhood ADHD, researchers have found, suggesting that there are two different syndromes with distinct developmental paths. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - July 25, 2016 Category: Psychiatry Tags: ADHD Source Type: research